Who makes BTL-TML-HSV?

BTL-TML-HSV is developed by Beech Tree Labs, Inc..

Last reviewed 2026-04-23 · How we verify

BTL-TML-HSV

Beech Tree Labs, Inc. · Phase 2 active Small molecule

BTL-TML-HSV, developed by Beech Tree Labs, is a novel treatment for oral herpes virus infection. It has completed Phase 1 and Phase 2 trials, demonstrating safety and efficacy in reducing recurrent symptoms. The drug is not yet FDA-approved but shows promise in treating UV-induced cold sores.

At a glance

Generic name	BTL-TML-HSV
Sponsor	Beech Tree Labs, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BTL-TML-HSV CI brief — competitive landscape report
BTL-TML-HSV updates RSS · CI watch RSS
Beech Tree Labs, Inc. portfolio CI